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Just like the 2009 Edinburgh Controversies meeting, the 
ﬁ   nal two sessions addressed the question of whether 
current drug development programmes for new agents in 
breast cancer are realising their full potential. However, 
this time the approach was to assess how various diﬀ  erent 
clinical studies/novel drugs are prioritised by either the 
pharmaceutical industry or by academic groups and 
investigators, and in addition how clinical trials in breast 
cancer are evolving in an era of targeted therapeutics. As 
in previous years, this was followed by an expert panel of 
representatives who debated the issues in an interactive 
fashion with the audience.
Dr Maria Koehler from Pﬁ  zer Oncology gave her own 
perspective of how the pharmaceutical industry is 
meeting the challenge of developing targeted therapeutics 
in an era of escalating costs and increasing regulatory 
requirements. Recognition that breast cancer contains a 
group of heterogeneous diseases with distinctive mole-
cular proﬁ   les has already led to notable success with 
endocrine therapy and trastuzumab. Increasingly, 
biomarker-directed subsets will be identiﬁ  ed  for 
development of the next generation of targeted thera-
peutics, and closer collaboration will be required than 
ever before between the pharmaceutical industry who 
have the novel drugs, molecular diagnostic companies 
who can develop biomarker testing, and academia/
clinical investigators who have access to patients and 
their tissue samples. Dr Koehler described some recent 
examples where results from translational studies 
modiﬁ  ed the development of novel targeted therapeutics, 
and emphasised that increasing collaboration and 
partner  ship will be required to develop the next 
generation of anti-cancer therapies.
Professor David Cameron discussed some of the issues 
around how clinical and translational research is 
con  ducted within the UK’s National Cancer Research 
Network (NCRN). One of the fundamental principles 
behind the NCRN is that research should map onto the 
delivery of clinical service within the National Health 
Service, and that with appropriate infrastructure in place 
it should then be feasible for most cancer patients to be 
considered for clinical trials within the NCRN’s portfolio 
of nationally run studies. Recruitment into cancer trials 
within the UK has been steadily increasing in recent 
years, and for breast cancer over 10% of patients are now 
being recruited into a randomised controlled trial, with 
an additional 15% recruited into non-randomised con-
trolled trials. Commercial studies are increasingly being 
added to the NCRN portfolio, and opportunities exist to 
enhance the link with Experimental Cancer Medicine 
Centres (ECMCs) so that greater access can be made to 
early phase clinical trials. In addition, partnerships with 
major pharmaceutical companies have been initiated to 
facilitate further investigator developed studies with 
targeted therapies.
Mr Alistair Th  ompson discussed how priorities are 
decided upon within the Breast Cancer Clinical Studies 
Group (CSG) of the National Cancer Research Institute 
(NCRI). Th  e three active subgroups cover the develop-
ment of trials in the adjuvant/neoadjuvant setting, 
initiatives in advanced/metastatic disease, and trans-
lational or biomarker/imaging-based studies. Individuals 
with good ideas, often with links to industry, can develop 
their concept through the Breast Cancer CSG and work 
up their protocol through engagement with a recognised 
accredited Clinical Trials Unit. Th  e Breast Cancer CSG 
then coordinates the overall strategy to ensure that there 
is no overlap of competing studies, at all times aiming to 
develop a broad-based portfolio of studies across the 
various subtypes and diﬀ  erent stages of breast cancer. 
Th   ere has been an increasing drive for industry studies to 
be included and adopted onto the portfolio. Th  rough  the 
Breast Cancer CSG there has been a signiﬁ  cant rise in the 
number of patients recruited into studies, with more than 
16,000 recruited in 2009/2010 alone, which represents 30 
to 45% of the UK’s incident breast cancer population. © 2010 BioMed Central Ltd
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addressed drug development in breast cancer from his 
own European perspective. He outlined that while 
previous trials in breast cancer over the past few decades 
have attempted to identify prognostic factors in breast 
cancer, modern studies in Europe are focussing on 
predictive biomarkers that will identify optimal beneﬁ  t 
from deﬁ   ned therapeutic regimens. Progress in breast 
cancer has been made with proliferation markers, growth 
factor recep  tors, and more recently gene expression 
proﬁ  ling, such that several ongoing international trials 
are now testing these concepts in prospective randomised 
studies. Trans  lational research and biomarker substudies 
should become an integral part of most phase I to III 
clinical trials. While in clinical practice we remain 
someway oﬀ    utilising all of this predictive molecular 
information in deciding an individualised or stratiﬁ  ed 
medicine strategy for each patient, the vision amongst 
academia and industry alike is that this should be 
achievable in the very near future.
Th  ere then followed an open discussion session in 
which the speakers were joined by other senior represen-
tatives from academia (Judith Bliss, Institute of Cancer 
Research; Bob Clarke, Washington), clinical investigation 
(John Robertson, Nottingham) and the pharmaceutical 
industry (Graham Ross, Roche), all of whom have been 
involved in development of novel therapies for breast 
cancer. Issues discussed included optimal trial design for 
targeted therapeutics, together with target validation in 
early studies. It remains clear that close collaboration 
between the pharmaceutical industry, academic institu-
tions and clinical investigators will remain crucial if the 
new era of targeted therapies is to be translated into 
signiﬁ   cant gains in clinical outcome for women with 
breast cancer.
Th   e session concluded with a plenary lecture from Dr 
Larry Norton, Memorial Sloane Kettering Cancer Centre, 
New York. He addressed where the ﬁ  eld of drug develop-
ment in breast cancer might be heading in relation to 
molecular proﬁ   ling and targeted therapies. Complex 
issues include the mathematics around the sheer number 
of genes of potential interest in molecular proﬁ  ling 
studies, including the number of interactions that can 
occur. Furthermore, systems biology means that intra-
cellular signalling networks have many redundant and 
compensatory pathways, making targeting of any single 
component potentially a futile approach. Robust systems 
in biology may be hard to perturb, but this could be 
overcome by smart combinations targeting multiple 
path  ways or immunological approaches. Our optimism 
for the future might need to be tempered by the 
realisation that targeted therapies might not cure breast 
cancer, that 100% predictive molecular response criteria 
may not be possible to generate, and that the next 
generation of modern therapeutics may be hard to aﬀ  ord.
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